Executive Leadership Team

The Executive Leadership Team (ELT) is responsible for setting and influencing Genomics England’s strategic direction (with the Board); defining, delivering and evaluating Genomics England’s activities: providing leadership, both inside the organisation and externally as ambassadors and thought leaders.

In 2013 Sir Mark Caulfield was appointed Chief Scientist for Genomics England, charged with delivery of the 100,000 Genomes Project on whole genome sequencing in rare disease, cancer and infection. The Chief Scientist’s team lead on all scientific activities for Genomics England.

Sir Mark engages with NHS scientific teams and the general public to promote, explains and enthuses about the 100,000 Genomes Project, and oversees the Clinical Interpretation Partnership and Access Review Committee. He is also responsible as Head of Profession (Science and Clinical) for helping us attract and retain the best scientific and clinical talent to the Project and ensuring our clinician community can develop professionally and appropriately within the Project.

Our Ethics team is also part of the Chief Scientist’s team, supporting Genomics England in its ethical governance of the Project, working in line with participants’ consent, the Project’s aims and advising on compliance with relevant medical, academic and data legislation, regulation including Research Ethics Committee (REC) approval, professional guidance and good ethical practice. This includes seeking input from patient groups and Project participants. The Ethics team leads on ethical policy issues, and provides the secretariat for the Ethics Advisory Committee and its standing subgroups on Equalities, Consent and Legacy (the future of mainstreamed NHS genomics beyond the Project).

Read more about Professor Sir Mark Caulfield

In January 2019, Sir Mark was appointed interim Chief Executive at Genomics England, and in June received a knighthood in the 2019 Queen’s Birthday Honours in recognition of his services to the 100,000 Genomes Project.

As COO and CFO at Genomics England, Graham is responsible for ensuring that the organisation’s overall operational efforts are delivering to our objectives and to stakeholder requirements, and for facilitating the development and evaluation of the corporate strategy and business plan.

Graham’s career spans over 25 years with management, commercial and leadership experience at senior levels in blue chip multinational companies with a turnover of up to $33bn.

Previous roles have included Finance Director, Vice President, Non-Executive Director and Chartered Accountant and prior to joining Genomics England, he was Global Head of Commercial Finance at AstraZeneca.

As Chief Commercial Officer and lead member of the Business and Investment Committee, Joanne is responsible for Genomics England’s industry engagement strategy; developing, managing and accelerating relationships with commercial organisations to create opportunities for collaboration both nationally and globally. Joanne is also responsible for the Research Environment, which enables researchers to work on our data.

This includes creating a portfolio of external investments and strategic alliances that advance technology and product strategies, and helping to meet research, development and commercialisation goals.

The Commercial Team is responsible for the administration of revenue and expenses to generate a financial return, working closely with all Genomics England teams and projects to identify and develop business opportunities.

Nick is an experienced and award winning commercial and procurement lawyer particularly in the health, transport and education sectors.

He is responsible for all legal activity within Genomics England including ensuring that the organisation complies with the law (Data Protection, Freedom of Information, Human Tissues Act) and the Company’s Articles and policies.

He is also responsible for signing off all procurement and contracting work.

Prior to his role at Genomics England, Nick was a partner in three Top 100 law firms: Pinsent Masons, DLA Piper and Bircham Dyson Bell.

Mark is seconded from the UK Department of Health & Social Care and helps to co-ordinate the various partnerships within the 100,000 Genomes Project. This includes the GeCIP domains, the MRC-funded work in Scotland, Wales, and Northern Ireland, and links with other international partners.

He oversees the running of key Boards and committees, including the GeCIP Board, Steering Group and the Access Review Committee.

He also supports wider strategic links with UK Department of Health & Social Care and other Government organisations.